Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics Inc
(NQ:
PTGX
)
41.44
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protagonist Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 03, 2023
Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share.
Via
Benzinga
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
July 03, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares...
Via
Benzinga
US Stocks Mixed; Dow Falls Over 50 Points
July 03, 2023
U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%...
Via
Benzinga
Where Protagonist Therapeutics Stands With Analysts
June 12, 2023
Via
Benzinga
Chart Of The Day: Protagonist Therapeutics - Wide Opinions
June 09, 2023
Via
Talk Markets
Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1
June 01, 2023
Via
Investor Brand Network
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
June 28, 2023
With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors.
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of
June 09, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
June 06, 2023
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 01, 2023
Via
ACCESSWIRE
Protagonist Therapeutics: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
4 Analysts Have This to Say About Protagonist Therapeutics
April 27, 2023
Via
Benzinga
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
March 15, 2023
Via
Benzinga
Why Protagonist Therapeutics Shares Are Trading Higher Today
March 07, 2023
Via
Benzinga
Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment
May 12, 2023
Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of
Via
Benzinga
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
May 05, 2023
The company is targeting psoriasis with a first-ever mechanism that could rival leaders.
Via
Investor's Business Daily
Why Shares of Protagonist Therapeutics Rose This Week
April 20, 2023
The company's lead pipeline candidate is making news.
Via
The Motley Fool
Why Protagonist Therapeutics Shares Are Nosediving
April 05, 2023
Protagonist Therapeutics Inc (NASDAQ: PTGX) shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 05, 2023
Via
Benzinga
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
April 04, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
April 04, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
March 15, 2023
Via
ACCESSWIRE
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
March 14, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 07, 2023
Via
Benzinga
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 07, 2023
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the...
Via
Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
March 07, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Top 5 Health Care Stocks That May Collapse In February
February 13, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Protagonist Therapeutics Earnings Perspective: Return On Capital Employed
August 25, 2022
Protagonist Therapeutics (NASDAQ:PTGX) brought in sales totaling $859 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 96.07%, resulting in a loss of $41.04...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 05, 2022
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.